Closed-loop hardware and self-oxygenating nanoformulation for hypoxic tumor theranostics

We introduce a patented, closed-loop theranostic platform engineered to overcome severe intratumoral hypoxia in solid tumors. The system unifies an environment-responsive hybrid nanocarrier with an external, algorithmic dual-channel nanophotonic irradiation hardware console. At tumor acidity (pH ~6.3), the outer polymeric shell undergoes targeted dissociation to trigger localized delivery.

The dual-channel hardware console integrates ultra-sensitive optical detection modules to map tumor boundaries in real-time via autonomous self-bioluminescence. Upon coordinate generation, it focalizes a 660 nm laser matrix to drive targeted destruction, while an embedded microcontroller executes an automated safety shut-off loop the moment tumor ablation is complete.

Empirical Validation & Efficacy:

• Monodisperse Stability: DLS and SEM confirmed high stability with a controlled hydrodynamic diameter of 122 ± 5 nm.
• Absolute Dark Safety: In vitro MTT assays on human breast adenocarcinoma cells (MCF-7) verified a baseline cell viability of 96.8% in the dark.
• Hypoxia-Independent Ablation: Under extreme hypoxic conditions (pO2 = 1%), 660 nm laser irradiation driven by the hardware console achieved a targeted tumor apoptosis rate of 91.8% to 94.5%, while commercial oxygen-dependent photosensitizers failed completely (<28.4% efficacy).
• High-Contrast Resolution: Generated a clean Signal-to-Noise Ratio (SNR) of 88:1 in deep hypoxic environments.

We are seeking strategic R&D collaborations, technology licensing, or co-development partnerships to advance this integrated platform into preclinical development.